Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab individualized treatment in treatment-naïve BRVO macular edema
ChiCTR2600123708Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of faricimab in branch retinal vein occlusion (BRVO), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Best Corrected Visual Acuity. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
faricimab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on ChiCTR2600123708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123708.